  In its more severe forms, COVID-19 progresses towards an excessive immune
response, leading to the systemic overexpression of proinflammatory cytokines
like IL6, mostly from the infected lungs. This cytokine storm can cause
multiple organ damage and death. Consequently, there is a pressing need to
identify therapies to treat and prevent severe symptoms during COVID-19. Based
on previous clinical evidence, we hypothesized that inhibiting T cell
co-stimulation by blocking CD80/86 could be an effective therapeutic strategy
against progression to severe proinflammatory states. To support this
hypothesis, we performed an analysis integrating blood transcriptional data we
generated from rheumatoid arthritis patients treated with abatacept -- a
CD80/86 co-stimulation inhibitor -- with the pathological features associated
with COVID-19, particularly in its more severe forms. We have found that many
of the biological processes that have been consistently associated with
COVID-19 pathology are reversed by CD80/86 co-stimulation inhibition, including
the downregulation of IL6 production. Also, analysis of previous
transcriptional data from blood of SARS-CoV-infected patients showed that the
response to abatacept has a very high level of antagonism to that elicited by
COVID-19. Finally, analyzing a recent single cell RNA-seq dataset from
bronchoalveolar lavage fluid cells from COVID-19 patients, we found a
significant correlation along the main elements of the C80/86 axis: CD86+/80+
antigen presenting cells, activated CD4+ T cells and IL6 production. Our
in-silico study provides additional support to the hypothesis that blocking of
the CD80/CD86 signaling axis may be protective of the excessive proinflammatory
state associated with COVID-19 in the lungs.
